The Role of Inflammation in Cholestasis: Clinical and Basic Aspects

ABSTRACT

Hepatobiliary transport systems are essential for the uptake and excretion of a variety of compounds including bile acids. Disruption and dysregulation of this excretory pathway result in cholestasis, leading to the intrahepatic accumulation of bile acids and other toxic compounds with progression of liver pathology. Cholestasis induced by inflammation is a common complication in patients with extrahepatic infections or inflammatory processes, generally referred to as sepsis-associated cholestasis. Microbial products, including endotoxin, induce signaling pathways within hepatocytes either directly, or through activation of proinflammatory cytokines, leading to rapid and profound reductions in bile flow. The expression and function of key hepatobiliary transporters are suppressed in response to inflammatory signaling. These proinflammatory signaling cascades lead to repressed expression and activity of a large number of nuclear transcriptional regulators, many of which are essential for maintenance of hepatobiliary transporter gene expression. Interestingly, recently discovered molecular crosstalk between bile acid activated nuclear receptors and proinflammatory nuclear mediators may provide new means of understanding adaptive processes within liver. Inflammation-induced cholestasis and the effects of retained molecules in cholestasis on inflammatory signals are interwoven in the liver, providing potential opportunities for research and therapeutics.

KEYWORDS

Liver - cholestasis - inflammation - transporters - bile acids

REFERENCES

• 1 Copple B L, Jaeschke H, Klaassen C D. Oxidative stress and the pathogenesis of cholestasis.  Semin Liver Dis. 2010;  30(2) 193-202
• 2 Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: Pathophysiology and clinical aspects.  Semin Liver Dis. 2010;  30(2) 132-144
• 3 Pauli-Magnus C, Meier P J, Stieger B. Genetic determinants of drug induced cholestasis and Intrahepatic Cholestasis of Pregnancy.  Semin Liver Dis. 2010;  30(2) 145-157
• 4 Paulusma C C, Oude Elferink R PJ, Jansen P LM. Progressive familial intrahepatic cholestasis type 1.  Semin Liver Dis. 2010;  30(2) 115-122
• 5 Lam P, Soroka C J, Boyer J L. The bile salt export pump: Clinical and experimental aspects of genetic and acquired cholestatic liver disease.  Semin Liver Dis. 2010;  30(2) 123-131
• 6 Soroka C J, Ballatori N, Boyer J L. Organic solute transporter, OSTalpha-OSTbeta: Its role in bile acid transport and cholestasis.  Semin Liver Dis. 2010;  30(2) 176-183
• 7 Wagner M, Zollner G, Trauner M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis.  Semin Liver Dis. 2010;  30(2) 158-175
• 8 Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis.  J Hepatol. 2009;  51(3) 565-580
• 9 Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases.  Br J Pharmacol. 2009;  156(1) 7-27
• 10 Stahl S, Davies M R, Cook D I, Graham M J. Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis.  Xenobiotica. 2008;  38(7-8) 725-777
• 11 Kosters A, Karpen S J. Bile acid transporters in health and disease.  Xenobiotica. 2008;  38(7-8) 1043-1071
• 12 Mulder J, Karpen S J, Tietge U J, Kuipers F. Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis.  Front Biosci. 2009;  14 2599-2630
• 13 Dawson P A, Lan T, Rao A. Bile acid transporters.  J Lipid Res. 2009;  50(12) 2340-2357
• 14 Teng S, Piquette-Miller M. Regulation of transporters by nuclear hormone receptors: implications during inflammation.  Mol Pharm. 2008;  5(1) 67-76
• 15 Geier A, Fickert P, Trauner M. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis.  Nat Clin Pract Gastroenterol Hepatol. 2006;  3(10) 574-585
• 16 Geier A, Wagner M, Dietrich C G, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration.  Biochim Biophys Acta. 2007;  1773(3) 283-308
• 17 Karpen S J, Trauner M. The new therapeutic frontier - Nuclear receptors and the liver.  J Hepatol. 2009;  , December 24 (Epub ahead of print)
• 18 Zollner G, Marschall H U, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations.  Mol Pharm. 2006;  3(3) 231-251
• 19 Moshage H. Cytokines and the hepatic acute phase response.  J Pathol. 1997;  181(3) 257-266
• 20 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation.  N Engl J Med. 1999;  340(6) 448-454
• 21 Baumann H, Gauldie J. The acute phase response.  Immunol Today. 1994;  15(2) 74-80
• 22 Trauner M, Fickert P, Stauber R E. Inflammation-induced cholestasis.  J Gastroenterol Hepatol. 1999;  14(10) 946-959
• 23 Trauner M, Wagner M, Fickert P, Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.  J Clin Gastroenterol. 2005;  39(4, Suppl 2) S111-S124
• 24 Nakamura J, Nishida T, Hayashi K et al.. Kupffer cell-mediated down regulation of rat hepatic CMOAT/MRP2 gene expression.  Biochem Biophys Res Commun. 1999;  255(1) 143-149
• 25 Xu D X, Wei W, Sun M F et al.. Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver.  Free Radic Biol Med. 2004;  37(1) 10-22
• 26 Sturm E, Havinga R, Baller J F et al.. Kupffer cell depletion with liposomal clodronate prevents suppression of Ntcp expression in endotoxin-treated rats.  J Hepatol. 2005;  42(1) 102-109
• 27 Ohlinger W, Dinges H P, Zatloukal K, Mair S, Gollowitsch F, Denk H. Immunohistochemical detection of tumor necrosis factor-alpha, other cytokines and adhesion molecules in human livers with alcoholic hepatitis.  Virchows Arch A Pathol Anat Histopathol. 1993;  423(3) 169-176
• 28 Luster M I, Germolec D R, Yoshida T, Kayama F, Thompson M. Endotoxin-induced cytokine gene expression and excretion in the liver.  Hepatology. 1994;  19(2) 480-488
• 29 Morland C M, Fear J, McNab G, Joplin R, Adams D H. Promotion of leukocyte transendothelial cell migration by chemokines derived from human biliary epithelial cells in vitro.  Proc Assoc Am Physicians. 1997;  109(4) 372-382
• 30 Fava G, Glaser S, Francis H, Alpini G. The immunophysiology of biliary epithelium.  Semin Liver Dis. 2005;  25(3) 251-264
• 31 Harada K, Ohira S, Isse K et al.. Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells.  Lab Invest. 2003;  83(11) 1657-1667
• 32 Chen X M, O'Hara S P, LaRusso N F. The immunobiology of cholangiocytes.  Immunol Cell Biol. 2008;  86(6) 497-505
• 33 Seki E, Brenner D A. Toll-like receptors and adaptor molecules in liver disease: update.  Hepatology. 2008;  48(1) 322-335
• 34 Geier A, Dietrich C G, Voigt S et al.. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver.  Am J Physiol Gastrointest Liver Physiol. 2005;  289(5) G831-G841
• 35 Ghose R, Zimmerman T L, Thevananther S, Karpen S J. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation.  Nucl Recept. 2004;  2(1) 4
• 36 Green R M, Beier D, Gollan J L. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents.  Gastroenterology. 1996;  111(1) 193-198
• 37 Trauner M, Arrese M, Lee H, Boyer J L, Karpen S J. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors.  J Clin Invest. 1998;  101(10) 2092-2100
• 38 Kosters A, White D D, Sun H, Thevananther S, Karpen S J. Redundant roles for cJun-N-terminal kinase 1 and 2 in interleukin-1beta-mediated reduction and modification of murine hepatic nuclear retinoid X receptor alpha.  J Hepatol. 2009;  51(5) 898-908
• 39 Geier A, Dietrich C G, Voigt S et al.. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis.  Hepatology. 2003;  38(2) 345-354
• 40 Kim P K, Chen J, Andrejko K M, Deutschman C S. Intraabdominal sepsis down-regulates transcription of sodium taurocholate cotransporter and multidrug resistance-associated protein in rats.  Shock. 2000;  14(2) 176-181
• 41 Denson L A, Auld K L, Schiek D S, McClure M H, Mangelsdorf D J, Karpen S J. Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation.  J Biol Chem. 2000;  275(12) 8835-8843
• 42 Karpen S J, Sun A Q, Kudish B et al.. Multiple factors regulate the rat liver basolateral sodium-dependent bile acid cotransporter gene promoter.  J Biol Chem. 1996;  271(25) 15211-15221
• 43 Thomas A M, Hart S N, Kong B et al.. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology (Baltimore, Md); 2009
• 44 Miura N, Tanaka K. Analysis of the rat hepatocyte nuclear factor (HNF) 1 gene promoter: synergistic activation by HNF4 and HNF1 proteins.  Nucleic Acids Res. 1993;  21(16) 3731-3736
• 45 Wang B, Cai S R, Gao C, Sladek F M, Ponder K P. Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4 alpha in rat liver.  Hepatology. 2001;  34(5) 979-989
• 46 Li T, Jahan A, Chiang J Y. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells.  Hepatology. 2006;  43(6) 1202-1210
• 47 Siewert E, Dietrich C G, Lammert F et al.. Interleukin-6 regulates hepatic transporters during acute-phase response.  Biochem Biophys Res Commun. 2004;  322(1) 232-238
• 48 Li N, Klaassen C D. Role of liver-enriched transcription factors in the down-regulation of organic anion transporting polypeptide 4 (oatp4; oatplb2; slc21a10) by lipopolysaccharide.  Mol Pharmacol. 2004;  66(3) 694-701
• 49 Hartmann G, Cheung A K, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia.  J Pharmacol Exp Ther. 2002;  303(1) 273-281
• 50 Cherrington N J, Slitt A L, Li N, Klaassen C D. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats.  Drug Metab Dispos. 2004;  32(7) 734-741
• 51 Zollner G, Fickert P, Zenz R et al.. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.  Hepatology. 2001;  33(3) 633-646
• 52 Trauner M. Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations.  Yale J Biol Med. 1997;  70(4) 365-378
• 53 Trauner M, Nathanson M H, Rydberg S A et al.. Endotoxin impairs biliary glutathione and HCO3- excretion and blocks the choleretic effect of nitric oxide in rat liver.  Hepatology. 1997;  25(5) 1184-1191
• 54 Geier A, Zollner G, Dietrich C G et al.. Cytokine-independent repression of rodent Ntcp in obstructive cholestasis.  Hepatology. 2005;  41(3) 470-477
• 55 Kubitz R, Wettstein M, Warskulat U, Häussinger D. Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone.  Gastroenterology. 1999;  116(2) 401-410
• 56 Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf D J, Suchy F J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor.  J Biol Chem. 2001;  276(31) 28857-28865
• 57 Gerloff T, Geier A, Roots I, Meier P J, Gartung C. Functional analysis of the rat bile salt export pump gene promoter.  Eur J Biochem. 2002;  269(14) 3495-3503
• 58 Kast H R, Goodwin B, Tarr P T et al.. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.  J Biol Chem. 2002;  277(4) 2908-2915
• 59 Plass J R, Mol O, Heegsma J et al.. Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump.  Hepatology. 2002;  35(3) 589-596
• 60 Karpen S J. Nuclear receptor regulation of hepatic function.  J Hepatol. 2002;  36(6) 832-850
• 61 Beigneux A P, Moser A H, Shigenaga J K, Grunfeld C, Feingold K R. The acute phase response is associated with retinoid X receptor repression in rodent liver.  J Biol Chem. 2000;  275(21) 16390-16399
• 62 Zimmerman T L, Thevananther S, Ghose R, Burns A R, Karpen S J. Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260.  J Biol Chem. 2006;  281(22) 15434-15440
• 63 Hisaeda K, Inokuchi A, Nakamura T et al.. Interleukin-1beta represses MRP2 gene expression through inactivation of interferon regulatory factor 3 in HepG2 cells.  Hepatology. 2004;  39(6) 1574-1582
• 64 Li D, Zimmerman T L, Thevananther S, Lee H Y, Kurie J M, Karpen S J. Interleukin-1 beta-mediated suppression of RXR:RAR transactivation of the Ntcp promoter is JNK-dependent.  J Biol Chem. 2002;  277(35) 31416-31422
• 65 Kim M S, Shigenaga J, Moser A, Feingold K, Grunfeld C. Repression of farnesoid X receptor during the acute phase response.  J Biol Chem. 2003;  278(11) 8988-8995
• 66 Fang C, Yoon S, Tindberg N, Järveläinen H A, Lindros K O, Ingelman-Sundberg M. Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure.  Biochem Pharmacol. 2004;  67(7) 1389-1397
• 67 Beigneux A P, Moser A H, Shigenaga J K, Grunfeld C, Feingold K R. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response.  Biochem Biophys Res Commun. 2002;  293(1) 145-149
• 68 Teng S, Piquette-Miller M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice.  J Pharmacol Exp Ther. 2005;  312(2) 841-848
• 69 Frankenberg T, Miloh T, Chen F et al.. The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor.  Hepatology. 2008; 
• 70 Donner M G, Warskulat U, Saha N, Häussinger D. Enhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS.  Biol Chem. 2004;  385(3-4) 331-339
• 71 Lee G, Piquette-Miller M. Cytokines alter the expression and activity of the multidrug resistance transporters in human hepatoma cell lines; analysis using RT-PCR and cDNA microarrays.  J Pharm Sci. 2003;  92(11) 2152-2163
• 72 Brcakova E, Fuksa L, Cermanova J et al.. Alteration of methotrexate biliary and renal elimination during extrahepatic and intrahepatic cholestasis in rats.  Biol Pharm Bull. 2009;  32(12) 1978-1985
• 73 Wang Y D, Chen W D, Wang M, Yu D, Forman B M, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.  Hepatology. 2008;  48(5) 1632-1643
• 74 Zhou C, Tabb M M, Nelson E L et al.. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation.  J Clin Invest. 2006;  116(8) 2280-2289
• 75 Xia X, Roundtree M, Merikhi A, Lu X, Shentu S, Lesage G. Degradation of the apical sodium-dependent bile acid transporter by the ubiquitin-proteasome pathway in cholangiocytes.  J Biol Chem. 2004;  279(43) 44931-44937
• 76 Chand N, Sanyal A J. Sepsis-induced cholestasis.  Hepatology. 2007;  45(1) 230-241
• 77 Osler W. Principles and Practice of Medicine 1901: p. 550
• 78 Dunham E C. Septicemia in the newborn.  Am J Dis Child. 1933;  45 229-253
• 79 Bernstein J, Brown A K. Sepsis and jaundice in early infancy.  Pediatrics. 1962;  29 873-882
• 80 Whitehead M W, Hainsworth I, Kingham J G. The causes of obvious jaundice in South West Wales: perceptions versus reality.  Gut. 2001;  48(3) 409-413
• 81 Moseley R H. Sepsis and cholestasis.  Clin Liver Dis. 2004;  8(1) 83-94
• 82 Bahador M, Cross A S. From therapy to experimental model: a hundred years of endotoxin administration to human subjects.  J Endotoxin Res. 2007;  13(5) 251-279
• 83 Santos A A, Wilmore D W. The systemic inflammatory response: perspective of human endotoxemia.  Shock. 1996;  6(Suppl 1) S50-S56
• 84 Pastor C M, Suter P M. Hepatic hemodynamics and cell functions in human and experimental sepsis.  Anesth Analg. 1999;  89(2) 344-352
• 85 Sherman M L, Spriggs D R, Arthur K A, Imamura K, Frei III E, Kufe D W. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.  J Clin Oncol. 1988;  6(2) 344-350
• 86 Jones A, Selby P J, Viner C, Hobbs S, Gore M E, McElwain T J. Tumour necrosis factor, cholestatic jaundice, and chronic liver disease.  Gut. 1990;  31(8) 938-939
• 87 Carter B A, Karpen S J. Intestinal failure-associated liver disease: management and treatment strategies past, present, and future.  Semin Liver Dis. 2007;  27(3) 251-258
• 88 Spencer A U, Neaga A, West B et al.. Pediatric short bowel syndrome: redefining predictors of success.  Ann Surg. 2005;  242(3) 403-409 discussion 409-412
• 89 Gura K M, Duggan C P, Collier S B et al.. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management.  Pediatrics. 2006;  118(1) e197-e201
• 90 Soden J S, Lovell M A, Brown K, Partrick D A, Sokol R J. Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure.  J Pediatr. 2010;  156(2) 327-331
• 91 Beath S V, Davies P, Papadopoulou A et al.. Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors.  J Pediatr Surg. 1996;  31(4) 604-606
• 92 Forrest E H, Oien K A, Dickson S, Galloway D, Mills P R. Improvement in cholestasis associated with total parenteral nutrition after treatment with an antibody against tumour necrosis factor alpha.  Liver. 2002;  22(4) 317-320
• 93 Arias I M, Gartner L M, Seifter S, Furman M. Prolonged neonatal unconjugated hyperbilirubinemia associated with breast feeding and a steroid, pregnane-3(alpha), 20(beta)-diol, in maternal milk that inhibits glucuronide formation in vitro.  J Clin Invest. 1964;  43 2037-2047
• 94 Heubi J E, Balistreri W F, Suchy F J. Bile salt metabolism in the first year of life.  J Lab Clin Med. 1982;  100(1) 127-136
• 95 Zollner G, Fickert P, Silbert D et al.. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.  J Hepatol. 2003;  38(6) 717-727
• 96 Boyer J L, Trauner M, Mennone A et al.. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents.  Am J Physiol Gastrointest Liver Physiol. 2006;  290(6) G1124-G1130
• 97 Oswald M, Kullak-Ublick G A, Paumgartner G, Beuers U. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis.  Liver. 2001;  21(4) 247-253
• 98 Wagner M, Zollner G, Trauner M. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation.  Hepatology. 2008;  48(5) 1383-1386
• 99 Wishart J. A link between rheumatoid arthritis and jaundice.  BMJ. 1903;  1 252
• 100 Hench P. Effect Of Jaundice On Chronic Infectious (Atrophic) Arthritis And On Primary Fibrositis: Further observations, attempts to reproduce the phenomenon.  Arch Intern Med. 1938;  61(3) 451-480
• 101 Hench P S. Recent Investigations on Rheumatism and Arthritis in the United States.  Ann Rheum Dis. 1940;  2(1) 19-40
• 102 Calmus Y, Guechot J, Podevin P, Bonnefis M T, Giboudeau J, Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes.  Hepatology. 1992;  16(3) 719-723